Ketamine for Multiple Sclerosis Fatigue

• Status: Not yet recruiting
• Trial end date: 2025-12-01

Summary

The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue.

• Phase: Phase 2

Details

• Lead Sponsor: Johns Hopkins University
• Collaborator: United States Department of Defense
• Treatments: Ketamine; Midazolam